Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will participate in Wonderland: Miami, presented by Microdose. The event is set to take place Nov. 8-9, 2021, in Miami, Florida. Tryp’s chairman and CEO Greg McKee will participate in a … Continue reading “NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Participate in Panel Discussion at Wonderland: Miami”
Related Editorial There isn’t a cigarette smoker in the world who doesn’t know smoking is bad for them. The problems are that nicotine is one of the most highly addictive substances in the world, and for the nearly 70% of 34.1 million Americans who want to kick the habit, there aren’t many smoking-cessation options that … Continue reading “NetworkNewsAudio – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers Hope on the Smoking-Cessation Horizon”
NetworkNewsWire Editorial Coverage: Global destigmatization, changing regulations and an upswing in research are speaking loudly to the opportunity for psychedelics to provide tangible improvements in medicine to address some of the most resistant, devastating and expensive conditions known to man. For decades, drugmakers have spent billions of dollars searching for therapies that can safely help … Continue reading “Psychedelics Offer Hope for Mental Disorders, Addiction”
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) to evaluate its clinical candidate, TRP-8802, in a phase 2a clinical trial. Conducted with Kevin … Continue reading “NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Submits IND Application to Evaluate Clinical Candidate in Phase 2a Trial in Fibromyalgia”
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced the list of entertainers that will be featured during its upcoming Meet Delic event. The event, scheduled for Nov. 6–7, 2021, in Las Vegas, is designed to be an immersive edutainment experience offering everything from … Continue reading “NetworkNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Releases Entertainment Lineup for Premiere Psychedelic, Wellness Event”
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is nearing the launch of a phase 2a clinical trial that aims to establish the value of its psychedelic drug candidate, TRP-8802, in treating chronic and severe eating disorders such as Prader-Willi Syndrome (“PWS”), hypothalamic obesity disorder resulting from the removal of a brain tumor, and binge eating dysfunction. … Continue reading “NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Way Through Unique Psychedelic Drug Development Focus”
NetworkNewsWire Editorial Coverage: There isn’t a cigarette smoker in the world who doesn’t know smoking is bad for them. The problems are that nicotine is one of the most highly addictive substances in the world, and for the nearly 70% of 34.1 million Americans who want to kick the habit, there aren’t many smoking-cessation options … Continue reading “Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Smoking Cessation and More”
In July, Tryp appointed Dr. Robin Carhart-Harris as the Chairman of its Scientific Advisory Board and Dr. Daniel Clauw, M.D., as a member Commenting on the appointments, Tryp Chairman and CEO Greg McKee expressed his appreciation at the pair’s commitment to the alleviation of chronic pain and other diseases with psychedelic-based therapies as well as … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Transforming Treatment of Fibromyalgia and Chronic Pain Conditions”
Sprout AI(CSE: SPRT), a technologically focused, sustainable vertical farming company that has developed scalable, AI-controlled aeroponic cultivation habitats, will be providing cultivation services for JT Medical. JT Medical has announced that it is accepting memorandums of understanding (“MOUs”) from researchers looking to obtain high-quality, repeatable batch, plant-based medical products derived from regulated plants. The company … Continue reading “NetworkNewsBreaks – Sprout AI Inc. (CSE: SPRT) to Provide Cultivation Services for Company Offering Plant-Based Medical Products”
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced that COMPASS Pathways execs George Goldsmith and Ekaterina Malievskaia MD will be featured speakers at next month’s Meet Delic event. Meet Delic is a revolutionary, two-day immersive edutainment experience designed to gather together the world’s leading … Continue reading “NetworkNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Names Keynote Speakers for World’s Premiere Psychedelic, Wellness Event”
